GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The number of patients needed to treat (NNT) to prevent an episode in 3 years was 66 for the primary outcome and 98 for death from any cause [60].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“The increase in cardiovascular disease (CVD) in patients with DM was already apparent in the Framingham (1979) [6] andMERIT (1993) clinical trials [7], which suggested that diabetic patients have a two- to fourfold risk of CVD compared to nondiabetic patients.”
BackgroundDiabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · cited 1×
“Nevertheless, cardiovascular disease continues to be the main complication and cause of death in the diabetic patient [4].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Thus, lixisenatide showed a neutral cardiovascular profile in patients with type 2 diabetes and a recent acute coronary syndrome [59].”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“4%, both significant against placebo [17, 18].”
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“8mg/day with dose escalation) versus exenatide (10μg/12 hours with dose titration) [19].”
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad211 · Cited by 210
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01090-x · Cited by 78
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Beyond 12 monthsStable dose Well-controlled HbA1c, prevention of long-term diabetes complications, weight loss maintained [123,124,132,158] Abbreviations: GLP-1—glucagon-like peptide-1; HbA1c—hemoglobin A1c.”
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Fushimi, N., Shibuya, T., Yoshida, Y., Ito, S., Hachiya, H., & Mori, A. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13093 · Cited by 41
Xie, D., Li, Y., Xu, M., Zhao, X., & Chen, M. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01634-1 · Cited by 42
“Some scholars think that this may be related to GLP-1RAs promoting the activity of NO synthase and increasing NO levels in endothelial cells [45].”
BackgroundAdvances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
“Furthermore, a meta-analysis that compiled data from the SUSTAIN-6 trial showed that CV benefits were associated with decreases in HbA1c and body weight [51].”
BackgroundMethodZhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Grewal, S., Zaman, N., Borgatta, L., Nudy, M., Foy, A. J., & Peterson, B. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.043 · Cited by 14
Metadata
- Authors
- del Olmo-Garcia, M. I., & Merino-Torres, J. F.
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2018-04-02
- Volume
- 2018
- Pages
- 1-12
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2795534327
- Cited by
- 138
- References
- 31
- FWCI
- 9.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.